Annual report pursuant to Section 13 and 15(d)

Related Party Transactions - Textual (Details)

v2.4.1.9
Related Party Transactions - Textual (Details) (USD $)
0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 0 Months Ended 12 Months Ended
Aug. 30, 2013
Sep. 30, 2009
Jun. 30, 2014
Oct. 31, 2013
Feb. 29, 2012
Dec. 31, 2012
Sep. 21, 2009
Jan. 16, 2014
Jan. 16, 2014
Jan. 02, 2014
Dec. 31, 2013
Jul. 31, 2012
Jun. 30, 2009
Dec. 31, 2012
sqft
Dec. 31, 2014
Dec. 31, 2013
Nov. 30, 2010
Jun. 30, 2010
Aug. 31, 2012
Nov. 30, 2007
sqft
Feb. 28, 2014
May 01, 2013
Dec. 31, 2015
Jan. 30, 2013
Aug. 31, 2011
Aug. 31, 2013
Jan. 31, 2013
Jul. 28, 2014
sqft
Sep. 21, 2011
Notes | Notes Due February 1, 2033                                                          
Related Party Transaction [Line Items]                                                          
Debt face amount                                               $ 175,000,000.0us-gaap_DebtInstrumentFaceAmount
/ us-gaap_DebtInstrumentAxis
= opk_NotesDueFebruary12033Member
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_ConvertibleNotesPayableMember
         
Convertible debt, stock issued from conversion 2,396,145us-gaap_DebtConversionConvertedInstrumentSharesIssued1
/ us-gaap_DebtInstrumentAxis
= opk_NotesDueFebruary12033Member
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_ConvertibleNotesPayableMember
                                                       
Convertible Preferred Stock [Member]                                                          
Related Party Transaction [Line Items]                                                          
Equity method investment, number of shares purchased   1,701,723opk_EquityMethodInvestmentNumberOfSharesPurchased
/ us-gaap_StatementClassOfStockAxis
= us-gaap_ConvertiblePreferredStockMember
                                                     
Common stock investments, available for sale | Notes | Notes Due February 1, 2033                                                          
Related Party Transaction [Line Items]                                                          
Convertible debt, stock issued from conversion     10,974,431us-gaap_DebtConversionConvertedInstrumentSharesIssued1
/ us-gaap_DebtInstrumentAxis
= opk_NotesDueFebruary12033Member
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_ConvertibleNotesPayableMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember
                                                   
ARNO                                                          
Related Party Transaction [Line Items]                                                          
Warrants to purchase common shares                             1,700,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                           
Zebra                                                          
Related Party Transaction [Line Items]                                                          
Invested in common shares       2,000,000us-gaap_PaymentsToAcquireEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
                                                 
Zebra | Series A Preferred Stock                                                          
Related Party Transaction [Line Items]                                                          
Investment Owned, Balance, Shares       840,000us-gaap_InvestmentOwnedBalanceShares
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember
                                                 
Investment ownership percentage       23.50%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember
                                                 
Zebra | Restricted Stock                                                          
Related Party Transaction [Line Items]                                                          
Shares Received As Gift       900,000opk_SharesReceivedAsGift
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RestrictedStockMember
                                                 
Chromadex Corporation                                                          
Related Party Transaction [Line Items]                                                          
Invested in common shares         1,000,000us-gaap_PaymentsToAcquireAvailableForSaleSecurities
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ChromadexCorporationMember
                                               
Beneficially owned held by owners         1.50%opk_AvailableforSaleSecuritiesOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ChromadexCorporationMember
                                               
Biozone Pharmaceuticals Inc                                                          
Related Party Transaction [Line Items]                                                          
Warrants to purchase common shares         8,500,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozonePharmaceuticalsIncMember
                                               
Invested in common shares           1,700,000us-gaap_PaymentsToAcquireAvailableForSaleSecurities
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozonePharmaceuticalsIncMember
                                             
Convertible senior notes interest rate         10.00%opk_NotesReceivableInterestRateStatedPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozonePharmaceuticalsIncMember
                                               
Par value         $ 0.20opk_NotesReceviableConvertibletoCommonStockConversionPrice
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozonePharmaceuticalsIncMember
                                               
Warrants duration         10 years                                                
Exercise price per share         $ 0.40invest_InvestmentWarrantsExercisePrice
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozonePharmaceuticalsIncMember
                                               
Fabrus Inc [Member]                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                                 13.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_FabrusIncMember
                       
Cocrystal                                                          
Related Party Transaction [Line Items]                                                          
Invested in common shares   2,500,000us-gaap_PaymentsToAcquireEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_CocrystalMember
        2,500,000us-gaap_PaymentsToAcquireEquityMethodInvestments
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_CocrystalMember
                                           
Warrants to purchase common shares                             1,000,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_CocrystalMember
                           
Equity Method Investee                                                          
Related Party Transaction [Line Items]                                                          
Private Placement Financing       30,000,000opk_PrivatePlacementFinancing
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
                                                 
Equity Method Investee | ARNO                                                          
Related Party Transaction [Line Items]                                                          
Invested in common shares       2,000,000us-gaap_PaymentsToAcquireEquityMethodInvestments
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                                                 
Investment Owned, Balance, Shares       833,333us-gaap_InvestmentOwnedBalanceShares
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                                                 
Investment Agreement, Requirement to Hold Rights to Board, Minimum Stock Percentage       3.00%opk_InvestmentAgreementRequirementtoHoldRightstoBoardMinimumStockPercentage
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                                                 
Related Party Transaction, Negotiation Period       45 days                                                  
Equity Method Investee | ARNO | One Year Warrants                                                          
Related Party Transaction [Line Items]                                                          
Warrants expiration period       1 year                                                  
Warrants to purchase common shares       833,333us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ClassOfWarrantOrRightAxis
= opk_OneYearWarrantsMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                                                 
Class of Warrant or Right, Exercise Price of Warrants or Rights       2.40us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
/ us-gaap_ClassOfWarrantOrRightAxis
= opk_OneYearWarrantsMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                                                 
Equity Method Investee | ARNO | Five Year Warrants                                                          
Related Party Transaction [Line Items]                                                          
Warrants expiration period       5 years                                                  
Warrants to purchase common shares       833,333us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ClassOfWarrantOrRightAxis
= opk_FiveYearWarrantsMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                                                 
Class of Warrant or Right, Exercise Price of Warrants or Rights       4.00us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
/ us-gaap_ClassOfWarrantOrRightAxis
= opk_FiveYearWarrantsMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                                                 
Equity Method Investee | Biozone                                                          
Related Party Transaction [Line Items]                                                          
Invested in common shares               500,000us-gaap_PaymentsToAcquireEquityMethodInvestments
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
                                         
Private Placement Financing               2,750,000opk_PrivatePlacementFinancing
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
                                         
Investment Owned, Balance, Shares               1,000,000us-gaap_InvestmentOwnedBalanceShares
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
1,000,000us-gaap_InvestmentOwnedBalanceShares
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
                                       
Warrants to purchase common shares               1,000,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
1,000,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
                                       
Class of Warrant or Right, Exercise Price of Warrants or Rights               0.50us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
0.50us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
                                       
Warrants duration                 10 years                                        
Convertible debt, stock issued from conversion                     10,000,000us-gaap_DebtConversionConvertedInstrumentSharesIssued1
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
                                   
Biozone Pharmaceuticals Warrants Exercised                       7,700,000opk_BiozonePharmaceuticalsWarrantsExercised
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
                                 
Stock Conversion, Common Shares Issued upon Conversion                   205.08opk_StockConversionCommonSharesIssueduponConversion
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
                                     
Equity Method Investee | Biozone | Series B Convertible Preferred Stock                                                          
Related Party Transaction [Line Items]                                                          
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued                   1,000,000us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozoneMember
/ us-gaap_StatementClassOfStockAxis
= opk_SeriesBConvertiblePreferredStockMember
                                     
Equity Method Investee | MusclePharm Corporation [Member] | Common stock investments, available for sale                                                          
Related Party Transaction [Line Items]                                                          
Noncash or Part Noncash Divestiture, Shares Received                   1,200,000opk_NoncashorPartNoncashDivestitureSharesReceived
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_MusclePharmCorporationMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_CommonStockMember
                                     
Equity Method Investee | Sorrento                                                          
Related Party Transaction [Line Items]                                                          
Invested in common shares                         2,300,000us-gaap_PaymentsToAcquireEquityMethodInvestments
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_SorrentoMember
                               
Investment ownership percentage                         33.33%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_SorrentoMember
                               
Equity Method Investment, Realized Gain (Loss) on Disposal                     17,200,000us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_SorrentoMember
                                   
Dr Frost                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                                                 36.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_DrFrostMember
       
Dr Frost | PROLOR                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                                                   5.00%opk_OwnershipPercentageHeldByMembers
/ dei_LegalEntityAxis
= opk_PROLORMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_DrFrostMember
     
Dr Frost | Zebra | Series A Preferred Stock                                                          
Related Party Transaction [Line Items]                                                          
Investment Owned, Balance, Shares       900,000us-gaap_InvestmentOwnedBalanceShares
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_DrFrostMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember
                                                 
Dr. Hsiao                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                                                 6.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Dr.HsiaoMember
       
Dr. Hsiao | PROLOR                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                                                   5.00%opk_OwnershipPercentageHeldByMembers
/ dei_LegalEntityAxis
= opk_PROLORMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Dr.HsiaoMember
     
Frost Gamma Investments Trust and Hsu Gamma Investment, L.P. | Notes | Notes Due February 1, 2033                                                          
Related Party Transaction [Line Items]                                                          
Debt face amount                                                     175,000,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_DebtInstrumentAxis
= opk_NotesDueFebruary12033Member
/ us-gaap_LongtermDebtTypeAxis
= us-gaap_ConvertibleNotesPayableMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostGammaInvestmentsTrustandHsuGammaInvestmentL.P.Member
   
Avi Properties LLC                                                          
Related Party Transaction [Line Items]                                                          
Period of lease                           5 years                              
Square feet of laboratory           44,000us-gaap_AreaOfLand
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_AviPropertiesLlcMember
              44,000us-gaap_AreaOfLand
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_AviPropertiesLlcMember
                             
Payments of lease per month           18,000opk_OperatingLeasesFutureMinimumPaymentsDuePerMonthYearOne
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_AviPropertiesLlcMember
              18,000opk_OperatingLeasesFutureMinimumPaymentsDuePerMonthYearOne
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_AviPropertiesLlcMember
                             
Exceeds consumer price index                           5.00%opk_LesseeLeasingArrangementsMinimumPercentageIncreaseInConsumerPriceIndexRequiredToIncreaseRentExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_AviPropertiesLlcMember
                             
Teva | FineTech                                                          
Related Party Transaction [Line Items]                                                          
Sale of API to TEVA           200,000us-gaap_RevenueFromRelatedParties
/ dei_LegalEntityAxis
= opk_FineTechMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_TevaPharmaceuticalIndustriesMember
                300,000us-gaap_RevenueFromRelatedParties
/ dei_LegalEntityAxis
= opk_FineTechMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_TevaPharmaceuticalIndustriesMember
300,000us-gaap_RevenueFromRelatedParties
/ dei_LegalEntityAxis
= opk_FineTechMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_TevaPharmaceuticalIndustriesMember
                         
Scripps Research Institute                                                          
Related Party Transaction [Line Items]                                                          
Fund for research agreement         900,000opk_RelatedPartyTransactionAgreementTermsAnnualFundForResearch
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_ScrippsResearchInstituteMember
                                               
Research agreement maturity period         5 years                                                
Approximate funding for development of technology         200,000opk_RelatedPartyTranscationAgreementTermsFurtherDevelopmentofTechnology
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_ScrippsResearchInstituteMember
                                               
Period for development of technology         3 years                                                
Gamma Trust | Chromadex Corporation                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members         16.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_GammaTrustMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ChromadexCorporationMember
                                               
Hsu Gamma | Chromadex Corporation                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members         1.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_HsuGammaMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ChromadexCorporationMember
                                               
Dr. Lerner | Sorrento                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                         1.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_DrLernerMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_SorrentoMember
                               
Gamma Trust and Hsu Gamma | Fabrus Inc [Member]                                                          
Related Party Transaction [Line Items]                                                          
Investment was part of financing for Fabrus                                 2,100,000opk_EquityMethodInvestmentAmountofFinancingIncludingRelatedParties
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_GammaTrustandHsuGammaMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_FabrusIncMember
                       
Academia Sinica                                                          
Related Party Transaction [Line Items]                                                          
Research and development agreement amount                                   200,000opk_DueToRelatedPartyOverTermOfAgreement
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_AcademiaSinicaMember
                     
Frost Group, LLC                                                          
Related Party Transaction [Line Items]                                                          
Previous investment by a group of investor   5,000,000opk_RelatedPartyTransactionPreviousInvestmentByGroupOfRelatedPartyInvestor
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostGroupLLCMember
                                                     
Additional investment by a group of investor   5,000,000opk_RelatedPartyTransactionAdditionalInvestmentPayableByGroupOfRelatedPartyInvestor
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostGroupLLCMember
                                                     
Number of equal installments payable for additional investment   2opk_RelatedPartyTransactionNumberofEqualInstallmentsPayableforAdditionalInvestmentbyRelatedPartyInvestors
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostGroupLLCMember
                                                     
Real Estate Holdings LLC                                                          
Related Party Transaction [Line Items]                                                          
Area of Real Estate Property                                                       22,000us-gaap_AreaOfRealEstateProperty
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
 
Square feet of laboratory                                       8,300us-gaap_AreaOfLand
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
                 
Payments of lease per month                                       18,000opk_OperatingLeasesFutureMinimumPaymentsDuePerMonthYearOne
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
                 
Lease rent per month for fifth year                                       24,000opk_OperatingLeasesFutureMinimumPaymentsDuePerMonthYearFive
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
                 
Credit for tenant improvements                             113,000us-gaap_TenantReimbursements
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
        30,000us-gaap_TenantReimbursements
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
                 
Period of lease agreement                                     6 months                    
Operating Leases, Monthly Payments, Year One                                                       57,000opk_OperatingLeasesMonthlyPaymentsYearOne
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
 
Operating Leases, Monthly Payments, Year Five                                                       65,000opk_OperatingLeasesMonthlyPaymentsYearFive
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
 
Tenant Improvements, Offset Against Operating Lease in Next Twelve Months                                                       216,000opk_TenantImprovementsOffsetAgainstOperatingLeaseinNextTwelveMonths
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
 
Mr. Rubin                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                                                 1.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Mr.RubinMember
       
Mr. Rubin | OPKO Biologics                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                                                   5.00%opk_OwnershipPercentageHeldByMembers
/ dei_LegalEntityAxis
= opk_OPKOBiologicsMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Mr.RubinMember
     
Mr. Rubin | Biozone Pharmaceuticals Inc                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members                                                         1.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Mr.RubinMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_BiozonePharmaceuticalsIncMember
Director | Chromadex Corporation                                                          
Related Party Transaction [Line Items]                                                          
Beneficially owned held by members         1.00%opk_OwnershipPercentageHeldByMembers
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_DirectorMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ChromadexCorporationMember
                                               
FTC Filings | Dr. Hsiao                                                          
Related Party Transaction [Line Items]                                                          
Payments for Filing Fees       170,000opk_PaymentsforFilingFees
/ us-gaap_RelatedPartyTransactionAxis
= opk_FTCFilingsMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Dr.HsiaoMember
                                280,000opk_PaymentsforFilingFees
/ us-gaap_RelatedPartyTransactionAxis
= opk_FTCFilingsMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Dr.HsiaoMember
               
Lab Space Agreement | Dr. Hsiao                                                          
Related Party Transaction [Line Items]                                                          
Area of Real Estate Property                                           5,000us-gaap_AreaOfRealEstateProperty
/ us-gaap_RelatedPartyTransactionAxis
= opk_LabSpaceAgreementMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Dr.HsiaoMember
             
Lessor Leasing Arrangements, Operating Leases, Term of Contract                                           5 years              
Consulting Agreement | Dr. Hsiao                                                          
Related Party Transaction [Line Items]                                                          
Contractual Obligation, Due in Fifth Year                                           60,000opk_OperatingLeasesAnnualMinimumPayment
/ us-gaap_RelatedPartyTransactionAxis
= opk_ConsultingAgreementMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_Dr.HsiaoMember
             
Loans Receivable | Fabrus                                                          
Related Party Transaction [Line Items]                                                          
Increase (Decrease) in Due from Related Parties       100,000us-gaap_IncreaseDecreaseInDueFromRelatedParties
/ us-gaap_RelatedPartyTransactionAxis
= us-gaap_LoansReceivableMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FabrusMember
                                                 
Related Party Transaction, Rate       7.00%us-gaap_RelatedPartyTransactionRate
/ us-gaap_RelatedPartyTransactionAxis
= us-gaap_LoansReceivableMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FabrusMember
                                                 
License Agreement Early Termination Fee | Equity Method Investee | Sorrento                                                          
Related Party Transaction [Line Items]                                                          
Related Party Transaction, Other Revenues from Transactions with Related Party                     2,700,000us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
/ us-gaap_RelatedPartyTransactionAxis
= opk_LicenseAgreementEarlyTerminationFeeMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= us-gaap_EquityMethodInvesteeMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_SorrentoMember
                                   
Reimbursement Of Travel Expense | Dr Frost                                                          
Related Party Transaction [Line Items]                                                          
Reimbursement paid to related party for travel           203,000us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
/ us-gaap_RelatedPartyTransactionAxis
= opk_ReimbursementOfTravelExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_DrFrostMember
                175,000us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
/ us-gaap_RelatedPartyTransactionAxis
= opk_ReimbursementOfTravelExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_DrFrostMember
93,000us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
/ us-gaap_RelatedPartyTransactionAxis
= opk_ReimbursementOfTravelExpenseMember
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_DrFrostMember
                         
Scenario, Forecast | Real Estate Holdings LLC                                                          
Related Party Transaction [Line Items]                                                          
Credit for tenant improvements                                             $ 103,000us-gaap_TenantReimbursements
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= opk_FrostRealEstateHoldingsLLCMember
/ us-gaap_StatementScenarioAxis
= us-gaap_ScenarioForecastMember
           
Sevion                                                          
Related Party Transaction [Line Items]                                                          
Investment ownership percentage                             4.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ invest_InvestmentAxis
= opk_SevionMember
                           
Cocrystal                                                          
Related Party Transaction [Line Items]                                                          
Investment ownership percentage                             8.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ invest_InvestmentAxis
= opk_CocrystalMember